| __timestamp | Sarepta Therapeutics, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 381287000 |
| Thursday, January 1, 2015 | 75043000 | 452612000 |
| Friday, January 1, 2016 | 83749000 | 316800000 |
| Sunday, January 1, 2017 | 122682000 | 330100000 |
| Monday, January 1, 2018 | 207761000 | 265800000 |
| Tuesday, January 1, 2019 | 284812000 | 336200000 |
| Wednesday, January 1, 2020 | 317875000 | 423900000 |
| Friday, January 1, 2021 | 282660000 | 467000000 |
| Saturday, January 1, 2022 | 451421000 | 487000000 |
| Sunday, January 1, 2023 | 481871000 | 477100000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, United Therapeutics Corporation and Sarepta Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. United Therapeutics consistently maintained higher SG&A expenses, peaking in 2022 with nearly 487 million USD, reflecting a strategic focus on robust administrative and sales operations. In contrast, Sarepta Therapeutics exhibited a more dynamic growth, with SG&A expenses surging by over 870% from 2014 to 2023, reaching approximately 482 million USD. This rapid increase underscores Sarepta's aggressive expansion and investment in administrative capabilities. The data highlights the contrasting strategies of these biotech giants, offering insights into their operational priorities and market positioning.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Sarepta Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Comparing SG&A Expenses: United Therapeutics Corporation vs Protagonist Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and MiMedx Group, Inc.